Browse Studies — Arctuva

Phase 1

A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide …

Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III

Estimated

~$10 – $7,500

Debiopharm International SANCT05765812

Phase 2

Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grad…

High Grade GliomaAstrocytomaAstrocytoma, Grade III+16 more

Estimated

~$10 – $8,750

Rigel PharmaceuticalsNCT06161974

The SUPRAMAX-study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent result…

GlioblastomaHigh-grade GliomaGlioblastoma, IDH-wildtype+9 more

Estimated

~$10 – $1,125

Jasper GerritsenNCT06118723

Phase 1

Phase I-II Study Evaluating HSV-tk + Valacyclovir Gene Therapy Combination With Radiotherapy and Chemotherapy for Recurrent Glioblastoma Multiforme

Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.

Glioblastoma MultiformeAstrocytoma, Grade III

Estimated

~$10 – $7,500

David Baskin MDNCT03596086